Biotechnology company Halozyme Therapeutics Inc (NASDAQ:HALO) said on Tuesday that it has successfully filed a Biologics License Application (BLA) for fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with the US Food and Drug Administration.
The BLA has been initiated by the company's partner Genentech, a member of the Roche Group.
According to Halozyme,the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous administration uses its ENHANZE drug delivery technology in combination with intravenous (IV)chemotherapy for treating eligible patients with HER2-positive breast cancer.
This BLA submission is based on positive results from Genentech's global Phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood and comparable efficacy and safety to standard IV infusions of Perjeta plus Herceptin and chemotherapy.
Halozyme's proprietary ENHANZE drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20), which has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously. This delivery has shown to reduce health care practitioner time required for administration and shorten time for drug administration.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories